Renal Intervention. Douglas E. Drachman, MD, FSCAI Division of Cardiology Vascular Medicine Section December 9, 2014
|
|
- Arron May
- 5 years ago
- Views:
Transcription
1 Renal Intervention Douglas E. Drachman, MD, FSCAI Division of Cardiology Vascular Medicine Section December 9, 2014
2 Disclosure Information Douglas E. Drachman, MD, FACC Abbott Vascular, Inc.: Advisory Board Atrium Medical Corporation: Research Grant Support idev Technologies, Inc.: Research Grant Support Lutonix/BARD: Research Grant Support Off-label use of products will be discussed in this presentation as indicated. Many stents used in the peripherial arterial circulation are indicated for biliary or tracheal application.
3 10-minute Objectives: Epidemiology and Pathophysiology of RAS Clinical Trials Data: Methodologic Considerations Patient Selection for Renal Artery Stenting Future Directions
4 Uncontrolled Hypertension is a Scourge 67.5 million HTN in US 33 million uncontrolled (BP >140/>90 ) Inertia, side effects, cost, non-compliance NHANES: 13,375 hypertensive patients Apparent treatment-resistance (>3 medications) 15.9% in phase 1 ( ) 28.0% in phase 2 ( ) Egan, et al. Circulation 2011;124:1046
5 HTN outcomes: Framingham, AHA A 5mmHg reduction in BP can promote: 14% reduction in stroke 9% reduction in heart disease 7% decrease in death
6 Renal Artery Stenosis More common than previously thought. General population Hypertensive population HTN & suspected CAD Malignant HTN Malignant HTN & renal insuffiency Incidence 0.1% 4.0% 10-20% 20-30% 30-40% Lesions tend to progress with time. Progressive renal insufficiency ensues. Jean WJ, et al. Cathet Cardiovasc Diagn 1994;32:8-10. Harding MB, et al. J Am Soc Neph 1992;2: Weber-Mzell D,et al. Eur Heart J 2002;23:
7 Renal Artery Revascularization: Why it should control HTN RAAS = the mechanism
8 Contemporary Trials: Ambiguous Findings DRASTIC (van Jaardsveld et al., NEJM 2000) PTA vs. Med-Rx (n=106) no change in SBP at one year Stenosis > 50% Avg 2 interventions/site over 4 years (selection bias) PTA without stent restenosis in 50% Intention to treat analysis (cross-over) ASTRAL (ASTRAL Investigators, NEJM 2009) Stent vs. Med-Rx (n=806) no change in SCr at one year Enrolled by RADUS (2/5 pts < 70% stenosis, 1/5 <50%) Selection bias: 2 pts/center/year Baseline Cr 2.0, but many with unilateral RAS Enrolled for HTN, but SCr endpoint
9 N Engl J Med. 2014;370:13-22.
10 Methods Open-label, randomized, international, multicenter controlled clinical trial All received medical therapy: BP, diabetes, and lipids to goal, with participants provided free: Candesartan ± hydrochlorothiazide (Atacand ) Atorvastatin + Amlodipine (Caduet ) Antiplatelet therapy N Engl J Med. 2014;370:13-22.
11 Inclusion Criteria Clinical syndrome: Hypertension 2 anti-hypertensive medications, OR Renal dysfunction defined as Stage 3 or greater CKD AND Atherosclerotic renal artery stenosis: Angiographic: 60% and <100%, OR Duplex: systolic velocity of >300 cm/sec, OR Core lab approved MRA, OR Core lab approved CTA N Engl J Med. 2014;370:13-22.
12 Primary Endpoint Composite of major cardiovascular or renal events: Cardiovascular or renal death Stroke Myocardial infarction Heart failure hospitalization Progressive renal insufficiency Permanent renal replacement therapy N Engl J Med. 2014;370:13-22.
13 Primary Endpoint N Engl J Med. 2014;370:13-22.
14 Results: Systolic Blood Pressure P=0.03 Note: BP reduced in med-rx group Were patients truly medically refractory /optimized? N Engl J Med. 2014;370:13-22.
15 Shortcomings of CORAL: Robust response to med-rx in control group Slow enrollment Patients with severe stenosis not enrolled Average stenosis 67% Equipoise? Is stenosis adequate to determine ischemia? Need for a hemodynamic evaluation? Are hard endpoints the correct ones?
16 Would you consider randomizing this patient to medical therapy? 78 yo F: - malignant HTN (>230/100mmHg) - 4 meds - Recur pulm edema - Intolerant of meds Renal Stenting it s all about case selection!
17 74 yo M with CRI ARF + cardiac disturbance syndrome one week after CEA Cr = 4.2, oliguric HD initiated Known RAS
18 74 yo M with CRI ARF + cardiac disturbance syndrome one week after CEA Cr = 4.2, oliguric HD initiated Known RAS
19 Selective engagement, attempted wiring ProWater Miracle Bros 3 Whisper IMA guide Sos 3 Sos 1
20 Anatomic insights from non-contrast CT can save the day: cul-de-sac lumen
21 Probing until Sos caught on a cleft, then Whisper Sos 1
22 Transition to HS guide: PTA, stent 6x18mm Herculink Elite Post-dil to 7mmm
23 Transition to HS guide: PTA, stent 6x18mm Herculink Elite Post-dil to 7mmm
24 Clinical response after renal stent Urine Output Stent Stent Serum Cr
25 Data support our ability to select patients
26 Study Overview Patient-level data from 901 patients (117 centers) 5 prospective multicenter FDA-approved IDE studies of renal artery stenting Associations of BP reduction determined by logistic regression Catheter Cardiovasc Intervent. 2014;83:603-9.
27 Included studies Study HERCULES Device RX Herculink Elite Number of Subjects 202 SOAR Bridge TM balloon expandable stent 186 RENAISSANCE Express SD Renal Premounted Stent System 100 RESTORE ASPIRE ParaMount XS DoubleStrut balloon expandable stent Palmaz Balloon expandable stent Catheter Cardiovasc Intervent. 2014;83: Selected Inclusion Criteria Uncontrolled BP and suboptimal PTA Uncontrolled BP and failed PTA Uncontrolled BP and suboptimal PTA, renal dysfunction (Cre<3.0 mg/dl), recurrent flash pulmonary edema, or any combination thereof Severe HTN Uncontrolled BP and suboptimal PTA
28 Blood Pressure Response Blood Pressure (mmhg) p< Pre Post 100 p< Systolic BP Catheter Cardiovasc Intervent. 2014;83: Diastolic BP
29 ACC/AHA Guidelines: Renal Revasc Hypertension Hemodynamically significant RAS Accelerated HTN Resistant HTN Malignant HTN HTN with unexplained unilateral small kidney HTN with intolerance to medication ØClass II indication, level of evidence = B Pulmonary edema ØClass I indication
30 SCAI expert consensus document Evaluation of literature Integration to clinical practice Catheter Cardiovasc Intervent
31 Appropriate Use Catheter Cardiovasc Intervent
32 Future Directions Transradial renal intervention PTFE-covered stenting
33 A recent consult for ARF,CHF, malignant HTN Our clinical dx: renal artery stenosis Our plan: renal intervention Multiple exams documented palpable but diminished distal pulses and femoral bruits To our exam: no palpable leg pulses Monophasic doppler at femorals
34 We found an I+ CT scan from prior admission
35 We used radial access
36 A Patient with Morbid Obesity We used radial access
37 Future Directions: PTFE-Covered Stents ARTISAN trial Externalization of atheromatous plaque? Reduction of restenosis?
38 Conclusions: HTN, RAS prevalent Clinical trials data: methodologic shortcomings Patient selection is key Transradial options to reduce vascular complications PTFE-covered stenting may offer promise
CORAL Trial Aftermath: What Do We Do Now? Renal Revascularization in Perspective
CORAL Trial Aftermath: What Do We Do Now? Renal Revascularization in Perspective Michael R. Jaff, DO Massachusetts General Hospital Boston, Massachusetts, USA Michael R. Jaff, DO Conflicts of Interest
More informationRenal Artery Stenting
Renal Artery Stenting J.P. Reilly, MD, FSCAI Ochsner Medical Center Speaker s bureau: Astra Zeneca and Lilly/Diachi Sankyo Prevalence of RAS is high in cath population. Renal artery intervention can help
More informationRenal Artery Stenosis: Insights from the CORAL Trial
Renal Artery Stenosis: Insights from the CORAL Trial Christopher J. Cooper, M.D., FACC, FACP Dean and Senior Vice President University of Toledo, College of Medicine President, Ohio Chapter ACC State of
More informationLife After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention
Life After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention No Relationships to Disclose The Need for Modern Renal Trials Increased rate of RAS diagnosis
More informationCurrent Role of Renal Artery Stenting in Patients with Renal Artery Stenosis
Current Role of Renal Artery Stenting in Patients with Renal Artery Stenosis Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea Etiology Fibromuscular
More informationSubclavian Revascularization. Douglas E. Drachman, MD, FSCAI Division of Cardiology Vascular Medicine Section December 9, 2014
Subclavian Revascularization Douglas E. Drachman, MD, FSCAI Division of Cardiology Vascular Medicine Section December 9, 2014 Disclosure Information Douglas E. Drachman, MD, FACC Abbott Vascular, Inc.:
More informationCoral Trials: A personal experience that challenges its results in patients with uncontrolled blood pressure.
Coral Trials: A personal experience that challenges its results in patients with uncontrolled blood pressure.. Dr. Javier Ruiz Aburto, FACS, FICS Assistant Professor Ponce School of Medicine Puerto Rico
More informationAppropriate Patient Identification For Renal Artery Intervention Remains Challenging
Renal Intervention Herbert D. Aronow, MD, MPH, FACC, FSCAI, FSVM Director, Interventional Cardiology, Cardiovascular Institute Director, Cardiac Cath Labs, Rhode Island &The Miriam Hospitals None Disclosures
More informationMichael Meuse, M.D. Vascular and Interventional Radiology
Michael Meuse, M.D. Vascular and Interventional Radiology Which patient would likely benefit from renal artery revascularization? Patient A- 60 y/o male with 20 year hx of htn; on 2 drug therapy for 10
More informationDisclosure of Potential Conflicts. Renal Artery Stenosis. RAS Epidemiology. Road Map. Background. ASDIN 7th Annual Scientific Meeting
Renal Artery Stenosis Disclosure of Potential Conflicts Cytopherx, Inc. R4 Vascular, Inc. Bard Peripheral Vascular Spectranetics, Inc. Alexander S. Yevzlin, MD Associate Professor of Medicine (CHS) ASDIN
More informationPCI for Renal Artery stenosis
PCI for Renal Artery stenosis Why should we treat Renal Artery Stenosis? Natural History of RAS RAS is progressive disease Study Follow-up (months) Pts Progression N (%) Total occlusion Wollenweber Meaney
More informationSCAI Fall Fellows Course Subclavian/Innominate Case Presentation
SCAI Fall Fellows Course 2012 Subclavian/Innominate Case Presentation Daniel J. McCormick DO, FACC, FSCAI Director, Cardiovascular Interventional Therapy Pennsylvania Hospital University of Pennsylvania
More informationRenal Artery FFR. Woo-Young Chung. Seoul National University, College of Medicine Boramae Medical Center Cardiovascular Center
Renal Artery FFR Woo-Young Chung Seoul National University, College of Medicine Boramae Medical Center Cardiovascular Center Why renal FFR? Renal artery angioplasty (PTRA) Indication of Renal artery angioplasty
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationMEET /06/2013 SESSION : RENAL AND VISCERAL
MEET 2003 11/06/2013 SESSION : RENAL AND VISCERAL AFTER 35 YEARS, WHAT ARE THE INDICATIONS AND RESULTS OF PTRA IN PATIENTS WITH RI OR RVH? THOMAS SOS, MD NYPH CORNELL New York, NY THOMAS SOS, MD NYPH CORNELL
More informationCase yr old lady; type 2 Diabetes 10 yrs; PVD; hypertension
Does this patient have flash pulmonary oedema? Philip A Kalra Professor of Nephrology, Salford Royal Hospital and University of Manchester, UK 73 yr old lady; type 2 Diabetes 1 yrs; PVD; hypertension Acute
More informationCarotid Artery Stenting (CAS) Pathophysiology. Technical Considerations. Plaque characteristics: relevant concepts. CAS and CEA
Carotid Artery Stenting (CAS) Carotid Artery Stenting for Stroke Risk Reduction Matthew A. Corriere MD, MS, RPVI Assistant Professor of Surgery Department of Vascular and Endovascular Surgery Rationale:
More informationIncidence and Prevalence of Atherosclerotic Renal Artery Stenosis (RAS) in Patients with Coronary Artery Disease (CAD)
Incidence and Prevalence of Atherosclerotic Renal Artery Stenosis (RAS) in Patients with Coronary Artery Disease (CAD) AHMW Islam, S Munwar, S Talukder, AQM Reza Dept. of Invasive & Interventional Cardiology,
More informationSecondary Hypertension: A Real World Approach
Secondary Hypertension: A Real World Approach Evan Brittain, MD December 7, 2012 Kingston, Jamaica Disclosures None Real World Causes Renovascular Hypertension Endocrine Obstructive Sleep Apnea Pseudosecondary
More informationRENAL ARTERY STENOSIS. Grand Rounds 10/11/2011
RENAL ARTERY STENOSIS Grand Rounds 10/11/2011 ARAS Prevalence- 0.5% overall population, 5.5% in ckd pts No correlation between ischemic nephropathy and severity of stenosis Increased risk of vascular events-
More informationImmediate Normalisation of Blood Pressure following Intervention in Functional Total Occlusion of Unilateral Renal Artery with an Atrophic Kidney
Immediate Normalisation of Blood Pressure following Intervention in Functional Total Occlusion of Unilateral Renal Artery with an Atrophic Kidney Dr Parminder Singh Otaal Assistant Professor Department
More informationComparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE) Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,
More informationTreating Hypertension from
Treating Hypertension from Initiation to Resistance: A Case Study Approach Michelle Krause, MD Division of Nephrology University of Arkansas for Medical Sciences Central Arkansas Veteran s Healthcare System
More informationPrOspective multicenter study of carotid artery stenting Usinng mer Stent OCEANUS study!!!
PrOspective multicenter study of carotid artery stenting Usinng mer Stent OCEANUS study!!! Prof Piotr Pieniazek MD PhD Jagiellonian University Institute of Cardiology, John Paul II Hospital Krakow, Poland
More informationManagement of In-stent Restenosis after Lower Extremity Endovascular Procedures
Management of In-stent Restenosis after Lower Extremity Endovascular Procedures Piotr Sobieszczyk, MD Associate Director, Cardiac Catheterization Laboratory Cardiovascular Division and Vascular Medicine
More informationTreatment Options for Angina
Treatment Options for Angina Interventional Cardiology Perspective Michael A. Robertson, M.D. 10/30/10 Prevalence of CAD in USA 15 million Americans with CAD 2 million diagnostic catheterizations 1 million
More informationRecanalization of Chronic Carotid Artery Occlusion Objective Improvement Of Cerebral Perfusion
Recanalization of Chronic Carotid Artery Occlusion Objective Improvement Of Cerebral Perfusion Paul Hsien-Li Kao, MD Assistant Professor National Taiwan University Medical School and Hospital ICA stenting
More informationAdvances in Cardiovascular Diagnosis and Therapy. No disclosure or conflicts. Outline
Advances in Cardiovascular Diagnosis and Therapy Firas Zahr, MD Assistant Professor of Medicine Interventional Cardiology University Of Iowa No disclosure or conflicts Outline What is new with revascularization?
More informationCarotid Artery Stenting
Carotid Artery Stenting JESSICA MITCHELL, ACNP CENTRAL ILLINOIS RADIOLOGICAL ASSOCIATES External Carotid Artery (ECA) can easily be identified from Internal Carotid Artery (ICA) by noticing the branches.
More informationPre-and Post Procedure Non-Invasive Evaluation of the Patient with Carotid Disease
Pre-and Post Procedure Non-Invasive Evaluation of the Patient with Carotid Disease Michael R. Jaff, D.O., F.A.C.P., F.A.C.C. Assistant Professor of Medicine Harvard Medical School Director, Vascular Medicine
More informationApproach to patient with hypertension. Dr. Amitesh Aggarwal
Approach to patient with hypertension Dr. Amitesh Aggarwal Definition A systolic blood pressure ( SBP) >139 mmhg and/or A diastolic (DBP) >89 mmhg. Based on the average of two or more properly measured,
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More informationBULgarian Carotid Artery Stenting versus Surgery Study (BULCASSS): Randomized single center trial
BULgarian Carotid Artery Stenting versus Surgery Study (): Randomized single center trial Ivo Petrov, M. Konteva, H. Dimitrov, K. Kichukov Tokuda Hospital Sofia Cardiology Department Background Carotid
More informationEECP THERAPY American College of Cardiology Rhode Island Chapter Primary Care Symposium Neil Brandon, MD, FACC September 29, 2010
EECP THERAPY American College of Cardiology Rhode Island Chapter Primary Care Symposium Neil Brandon, MD, FACC September 29, 2010 Refractory Angina: Extent of Problem 6.4 Million Angina Patients in US
More informationFFR-CT Not Ready for Primetime
FFR-CT Not Ready for Primetime Leslee J. Shaw, PhD, MASNC, FACC, FAHA, FSCCT R. Bruce Logue Professor of Medicine Co-Director, Emory Clinical CV Research Institute Emory University School of Medicine Atlanta,
More informationPeter A. Soukas, M.D., FACC, FSVM, FSCAI, RPVI
Peter A. Soukas, M.D., FACC, FSVM, FSCAI, RPVI Director, Peripheral Vascular Interventional Laboratory Director, Vascular & Endovascular Medicine Fellowship Program Assistant Professor of Medicine The
More informationDuplex Ultrasound of the Renal Arteries. Duplex Ultrasound. In the Beginning
Duplex Ultrasound of the Renal Arteries DIMENSIONS IN HEART AND VASCULAR CARE 2013 PENN STATE HEART AND VASCULAR INSTITUTE ROBERT G. ATNIP MD PROFESSOR OF SURGERY AND RADIOLOGY Duplex Ultrasound Developed
More informationVivek R. Deshmukh, MD Director, Cerebrovascular and Endovascular Neurosurgery Chairman, Department of Neurosurgery Providence Brain and Spine
Vivek R. Deshmukh, MD Director, Cerebrovascular and Endovascular Neurosurgery Chairman, Department of Neurosurgery Providence Brain and Spine Institute The Oregon Clinic Disclosure I declare that neither
More informationManagement of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018
Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management
More informationSBP in range of 120 to 140 :no progression or regression of CAD. Sipahi et al., 2006
Management of Hypertension in Patients with CAD M. Mohsen Ibrahim, MD Cardiology Department- Cairo University 1. What is the optimal BP in patients with hypertension and CAD? 2. What is the minimum safe
More informationImaging Strategy For Claudication
Who are the Debators? Imaging Strategy For Claudication Duplex Ultrasound Alone is Adequate to Select Patients for Endovascular Intervention - Pro: Dennis Bandyk MD No Disclosures PRO - Vascular Surgeon
More informationMasahiko Fujihara, MD
Verify the efficacy of renal artery stenting to define the predictive factors by physiological assessment with pressure wire gradient VERDICT study Masahiko Fujihara, MD Kishiwada Tokushukai Hospital Osaka,
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ABI. See Ankle-brachial index (ABI). Afterload, deconstructing of, in ventricular vascular interaction in heart failure, 449 Air plethysmography
More informationHow to assess the hemodynamic importance of a renal artery stenosis. Felix Mahfoud, MD Saarland University Hospital Homburg/Saar, Germany
How to assess the hemodynamic importance of a renal artery stenosis Felix Mahfoud, MD Saarland University Hospital Homburg/Saar, Germany How to assess renal artery stenosis severity 1. Non-invasive assessments
More informationCarotid Artery Revascularization: Current Strategies. Shonda Banegas, D.O. Vascular Surgery Carondelet Heart and Vascular Institute September 6, 2014
Carotid Artery Revascularization: Current Strategies Shonda Banegas, D.O. Vascular Surgery Carondelet Heart and Vascular Institute September 6, 2014 Disclosures None 1 Stroke in 2014 Stroke kills almost
More informationRenal Artery Disease. None > 65,000,000. Learning objectives: Renal Artery Disease
Renal Artery Disease Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Financial Disclosure Information Renal Artery Disease Robert McBane, MD None To appreciate: Learning objectives:
More informationBridging With Percutaneous Devices: Tandem Heart and Impella
Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED HEART FAILURE, TX AND MCS SENTARA HEART HOSPITAL NORFOLK, VA PROFESSOR OF MEDICINE
More informationDisclosures. CREST Trial: Summary. Lecture Outline 4/16/2015. Cervical Atherosclerotic Disease
Disclosures Your Patient Has Carotid Bulb Stenosis and a Tandem Intracranial Stenosis: How Do SAMMPRIS and Other Evidence Inform Your Treatment? UCSF Vascular Symposium 2015 Steven W. Hetts, MD Associate
More informationStroke Update Elaine J. Skalabrin MD Medical Director and Neurohospitalist Sacred Heart Medical Center Stroke Center
Stroke Update 2015 Elaine J. Skalabrin MD Medical Director and Neurohospitalist Sacred Heart Medical Center Stroke Center Objectives 1. Review successes in systems of care approach to acute ischemic stroke
More informationCatheter-Based Renal Sympathetic Denervation in the Management of Resistant Hypertension
Catheter-Based Renal Sympathetic Denervation in the Management of Resistant Hypertension Henry Krum, Markus Schlaich, Paul Sobotka, Rob Whitbourn, Jerzy Sadowski, Krzysztof Bartus, Boguslaw Kapelak, Horst
More informationAssessing Myocardium at Risk: Applying SYNTAX
Assessing Myocardium at Risk: Applying SYNTAX Farouc Jaffer MD PhD FSCAI FACC FAHA Associate Professor of Medicine, Harvard Medical School Director, CAD Program and Chronic Total Occlusion PCI Program
More informationThe CARENET all-comer trial using the CGuard micronet covered carotid embolic prevention stent
The CARENET all-comer trial using the CGuard micronet covered carotid embolic prevention stent 6 month data Piotr Musialek, MD DPhil FESC Jagiellonian University Dept. of Cardiac & Vascular Diseases John
More informationBlood Pressure LIMBO How Low To Go?
Blood Pressure LIMBO How Low To Go? Joseph L. Kummer, MD, FACC Bryan Heart Spring Conference April 21 st, 2018 Hypertension Epidemiology Over a billion people have hypertension Major cause of morbidity
More informationDisclosures. Carotid artery stenting. Surveillance after Endovascular Intervention: When to Re-Intervene and What s the Evidence
Disclosures Surveillance after Endovascular Intervention: When to Re-Intervene and What s the Evidence None 2015 UCSF Vascular Symposium Warren Gasper, MD Assistant Professor of Surgery UCSF Division of
More informationManagement of Carotid Disease CHRISTOPHER LAU PGY-3 BROOKLYN VA
Management of Carotid Disease CHRISTOPHER LAU PGY-3 BROOKLYN VA SUNY DOWNSTATE MEDICAL CENTER Case 61 year old male referred to Vascular Surgery for left internal carotid stenosis Presented with transient
More informationNew Trials in Progress: ACT 1. Jon Matsumura, MD Cannes, France June 28, 2008
New Trials in Progress: ACT 1 Jon Matsumura, MD Cannes, France June 28, 2008 Faculty Disclosure I disclose the following financial relationships: Consultant, CAS training director, and/or research grants
More informationContemporary Management of Carotid Disease What We Know So Far
Contemporary Management of Carotid Disease What We Know So Far Ammar Safar, MD, FSCAI, FACC, FACP, RPVI Interventional Cardiology & Endovascular Medicine Disclosers NONE Epidemiology 80 % of stroke are
More informationVCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital
VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital Complex PCI: Multivessel Disease George W. Vetrovec, MD. Kimmerling Chair of Cardiology VCU Pauley Heart Center Virginia
More informationDisclosures. Talking Points. An initial strategy of open bypass is better for some CLI patients, and we can define who they are
An initial strategy of open bypass is better for some CLI patients, and we can define who they are Fadi Saab, MD, FASE, FACC, FSCAI Metro Heart & Vascular Metro Health Hospital, Wyoming, MI Assistant Clinical
More informationTherapy for Acute Stroke. Systems of Care for TIA
Therapy for Acute Stroke and Systems of Care for TIA Gregory W. Albers, MD Coyote Foundation Professor of Neurology and Neurological Sciences Director, Stanford Stroke Center Stanford University Medical
More informationA Closer Look: Renal Artery Stenosis. Renal artery stenosis (RAS) is defined as a TOPICS FROM CHEP. Shawn s stenosis
TOPICS FROM CHEP A Closer Look: Renal Artery Stenosis On behalf of the Canadian Hypertension Education Program (CHEP), Dr. Tobe gives an overview of renal artery stenosis, including the prevalence, screening
More informationPredictors of restenosis and cardiovascular events in patients undergoing percutaneous angioplasty for subclavian/innominate artery stenosis
Predictors of restenosis and cardiovascular events in patients undergoing percutaneous angioplasty for subclavian/innominate artery stenosis Tadeusz Przewlocki, Anna Kablak Ziembicka, Piotr Pieniazek,
More informationThe BATTLE Trial Comparing Bare Metal to Drug Eluting Stents for Intermediate Length Lesions of the SFA
The BATTLE Trial Comparing Bare Metal to Drug Eluting Stents for Intermediate Length Lesions of the SFA BATTLE RCT investigators: Y. Gouëffic, A. Sauguet, P. Desgranges, P. Feugier, E. Rosset, E. Ducasse,
More informationCauses of death in Diabetes
Rates of CV events in Diabetes patients Respiratory4.2 Cancer 7.6 Diabetes 1.3 CV disease 17.3 Causes of death in Diabetes 250 200 150 100 50 0 per 10,000 person-years 97 151 243 Framingham 5 X increase
More informationDCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes
DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes Carlos Mena, MD FACC FSCAI Associate Professor of Medicine - Cardiology Director Cardiac
More informationAnimesh Rathore, MD 4/22/17. The Great Debate 45yo Man With Uncomplicated Acute TBAD: The Case For Medical Management
Animesh Rathore, MD 4/22/17 The Great Debate 45yo Man With Uncomplicated Acute TBAD: The Case For Medical Management Disclosures Just a young vascular surgeon who would like to keep his job My opponent
More informationHYPERTENSION: UPDATE 2018
HYPERTENSION: UPDATE 2018 From the Cardiologist point of view Richard C Padgett, MD I have no disclosures HYPERTENSION ALWAYS THE ELEPHANT IN THE EXAM ROOM BUT SOMETIMES IT CHARGES HTN IN US ~78 million
More informationHow to Choose Between Carotid Stenting and Carotid Endarterectomy for Stroke Prevention
How to Choose Between Carotid Stenting and Carotid Endarterectomy for Stroke Prevention Christopher J. White MD, MSCAI Chief of Medical Services, Professor and Chairman of Medicine Ochsner Medical Center
More informationCindy L. Grines MD FACC FSCAI
Cindy L. Grines MD FACC FSCAI Hofstra Northwell School of Medicine Chair, Cardiology Academic Chief of Cardiology, Northwell Health North Shore University Hospital, Manhasset NY Multivessel Disease in
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationThe earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College
The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP
More information11 TH ANNUAL VASCULAR NONINVASIVE TESTING SYMPOSIUM NOVEMBER 10, 2018
11 TH ANNUAL VASCULAR NONINVASIVE TESTING SYMPOSIUM NOVEMBER 10, 2018 RENAL ARTERY DISEASE AND RENOVASCULAR HYPERTENSION 1 WHAT IS RENOVASCULAR HYPERTENSION? https://my.clevelandclinic.org/health/diseases/16459-renovascular-hypertension
More informationRenal artery stenosis
Renal artery stenosis Dr. Alexander Woywodt Consultant Renal Physician, Royal Preston Hospital Preston, 31.10.2007 Menu anatomy of the renal arteries diseases of the large renal arteries atherosclerotic
More informationDISRUPT CAD. Todd J. Brinton, MD Clinical Associate Professor of Medicine Adjunct Professor of Bioengineering Stanford University
DISRUPT CAD A multicenter, prospective, single-arm study of percutaneous Lithoplasty prior to stent implantation in heavily calcified coronary lesions Todd J. Brinton, MD Clinical Associate Professor of
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationAtherectomy: Jetstream and Directional. George S. Chrysant, M.D.
Atherectomy: Jetstream and Directional George S. Chrysant, M.D. Disclosures Abbott Vascular: MAB, consultant, proctor Abiomed: consultant Boston Scientific: MAB, consultant, proctor Medicines Company:
More informationPRISM Trial. Retrospective Case Review of Technical Success Using the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery
PRISM Trial Retrospective Case Review of Technical Success Using the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery George L. Adams, MD, MHS, FACC, FSCAI Clinical Associate Professor
More informationTOBA II 12-Month Results Tack Optimized Balloon Angioplasty
TOBA II 12-Month Results Tack Optimized Balloon Angioplasty William Gray, MD System Chief, Cardiovascular Division Main Line Health, Philadelphia, PA Dissection: The Primary Mechanism of Angioplasty Lesions
More informationParis, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators
Paris, August 28 th 2011 Is TAVI the definitive treatment in high risk patients? Impact Of Coronary Artery Disease In Elderly Patients Undergoing TAVI: Insight The Italian CoreValve Registry Gian Paolo
More informationSurgical Treatment of Carotid Disease
Department of Cardiothoracic & Vascular Surgery McGovern Medical School / The University of Texas Health Science Center at Houston Surgical Treatment of Carotid Disease The Old, the New, and the Future
More informationRAS Epidemiology. Renal Artery Stenosis. Pathophysiology of RAS. Disclosure of Potential Conflicts. Background Pathophysiology of RAS.
Renal Artery Stenosis RAS Epidemiology Common Disease Incidence General Population 0.1% Hypertensive Population 4% HTN & Suspected CAD 10-20% Malignant HTN 20-30% Malignant HTN and CKD 30-40% Alexander
More informationJ-curve Revisited. An Analysis of Blood Pressure and Cardiovascular Events in the Treating to New Targets (TNT) Trial
J-curve Revisited An Analysis of Blood Pressure and Cardiovascular Events in the Treating to New Targets (TNT) Trial Sripal Bangalore, MD, MHA, Franz H Messerli, MD, Chuan-Chuan Wun, PhD, Andrea L. Zuckerman,
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationWilliam A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, PA USA
William A. Gray MD System Chief of Cardiovascular Services, President, Wynnewood, PA USA Why atherectomy? Calcification is the norm not the exception Most trials do not include heavy calcification There
More informationPATIENT SPECIFIC STRATEGIES IN CRITICAL LIMB ISCHEMIA. Dr. Manar Trab Consultant Vascular Surgeon European Vascular Clinic DMCC Dubai, UAE
PATIENT SPECIFIC STRATEGIES IN CRITICAL LIMB ISCHEMIA Dr. Manar Trab Consultant Vascular Surgeon European Vascular Clinic DMCC Dubai, UAE Disclosure Speaker name: DR. Manar Trab I have the following potential
More informationBifurcation stenting with BVS
Bifurcation stenting with BVS Breaking the limits or just breaking the struts? Maciej Lesiak Department of Cardiology University Hospital in Poznan, Poland Disclosure Speaker s name: Maciej Lesiak I have
More informationEvidence-Based Management of CAD: Last Decade Trials and Updated Guidelines
Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines Enrico Ferrari, MD Cardiac Surgery Unit Cardiocentro Ticino Foundation Lugano, Switzerland Conflict of Interests No conflict
More informationDISCLOSURE TEST YOUR WAVEFORM IQ. Partial volume artifact. 86 yo female with right arm swelling, picc line. AVF on left? Dx?
Deborah Rubens University of Rochester Rochester, NY DISCLOSURE Neither I nor my immediate family have a financial relationship with a commercial organization that may have a direct or indirect interest
More informationIN.PACT AV Access IDE Study Full Baseline Data. Robert Lookstein, MD MHCDL New York, NY On Behalf of the IN.PACT AV ACCESS Investigators
IN.PACT AV Access IDE Study Full Baseline Data Robert Lookstein, MD MHCDL New York, NY On Behalf of the IN.PACT AV ACCESS Investigators Disclosures Speaker name: Robert Lookstein, MD... I have the following
More informationEndovascular and Hybrid Treatment of TASC C & D Aortoiliac Occlusive Disease
Endovascular and Hybrid Treatment of TASC C & D Aortoiliac Occlusive Disease Arash Bornak, MD FACS Vascular & Endovascular Surgery University of Miami Miller School of Medicine No disclosure BACKGROUND
More informationVascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital
Vascular disease. Structural evaluation of vascular disease Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital resistance vessels : arteries
More informationReview of Cardiac Imaging Modalities in the Renal Patient. George Youssef
Review of Cardiac Imaging Modalities in the Renal Patient George Youssef ECHO Left ventricular hypertrophy (LVH) assessment Diastolic dysfunction Stress ECHO Cardiac CT angiography Echocardiography - positives
More informationDrug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort
Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort a.o. Univ. Prof. Dr. Marianne Brodmann Medical University of Graz Graz,
More informationLeft Main Intervention: Will it become standard of care?
Left Main Intervention: Will it become standard of care? David Cox, MD FSCAI, FACC Director, Interventional Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown,
More informationOstial Stents and Distal Embolic Protection During Renal Stenting
Ostial Stents and Distal Embolic Protection During Renal Stenting John R. Laird, MD Professor of Medicine Director of the Vascular Center UC Davis Medical Center Limitations of Current Techniques of Renal
More informationCryptogenic Stroke: A logical approach to a common clinical problem
Cryptogenic Stroke: A logical approach to a common clinical problem Alphonse M. Ambrosia, DO, FACC Interventional Cardiologist CardioVascular Associates of Mesa Mesa, Arizona Speakers Bureau Boston Scientific
More informationCoral Reef Aorta- Treatment Options?
Chronic mesenteric ischemia (CMI) Coral Reef Aorta- Treatment Options? Bala Ramanan Vascular Fellow, UCSF CMI is a life-threatening problem that can result in death from inanition or bowel infarction Incidence
More informationTreatment Considerations for Carotid Artery Stenosis. Danielle Zielinski, RN, MSN, ACNP Rush University Neurosurgery
Treatment Considerations for Carotid Artery Stenosis Danielle Zielinski, RN, MSN, ACNP Rush University Neurosurgery 4.29.2016 There is no actual or potential conflict of interest in regards to this presentation
More informationAllinaHealthSystem 1
: Definition End-organ hypoperfusion secondary to cardiac failure Venoarterial ECMO: Patient Selection Michael A. Samara, MD FACC Advanced Heart Failure, Cardiac Transplant & Mechanical Circulatory Support
More informationCarotid Artery Stent: Is it ready for prime time?
2010 CATH LAB SYMPOSIUM Carotid Artery Stent: Is it ready for prime time? Luis F. Tami, MD, FACC, FSCAI Interventional Cardiology and Vascular Medicine Memorial Regional Hospital August 2010 CAE and CAS
More information